Abstract
Staphylococcus aureus is one of the most common causes of hospital- and community-acquired infections. Since the recognition of vancomycin-resistant enterococci in 1988, the emergence of vancomycin-resistant S. aureus (VRSA) (minimum inhibitory concentration [MIC] > or = 32 microg/mL) has been anticipated. The transfer of the genetic element containing the vanA vancomycin resistance gene from Enterococcus faecalis to S. aureus was demonstrated in the laboratory in 1992; the first clinical infection with VRSA was reported in July 2002. This report describes the second documented clinical isolate of VRSA from a patient.
MeSH terms
-
Bacterial Proteins / genetics
-
Carbon-Oxygen Ligases / genetics
-
Carrier Proteins / genetics
-
Hexosyltransferases*
-
Humans
-
Muramoylpentapeptide Carboxypeptidase / genetics
-
Penicillin-Binding Proteins
-
Pennsylvania / epidemiology
-
Peptidyl Transferases*
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / epidemiology
-
Staphylococcal Infections / microbiology*
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / genetics
-
Vancomycin Resistance* / genetics
Substances
-
Bacterial Proteins
-
Carrier Proteins
-
Penicillin-Binding Proteins
-
VanA ligase, Bacteria
-
Peptidyl Transferases
-
Hexosyltransferases
-
Muramoylpentapeptide Carboxypeptidase
-
Carbon-Oxygen Ligases